Lilly and Boehringer Ingelheim's (BI) Abasaglar is the first biosimilar version of the top-selling insulin analogue to hit western European markets, and could eventually take a sizeable market share.

Pharmaceutical company Eli Lilly announced promising clinical trial results this week for a daily pill to treat obesity and diabetes. Besides the good news of minimal side effects and impressive ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other Billionaire Ken Fisher’s healthcare stock picks with massive upside potential.

PARIS, April 27 (Reuters) - Jordan Bardella plans to be the French far-right National Rally's presidential candidate in 2027 if the party's leader Marine Le Pen remains barred from running ...

Pen Argyl Area High School students celebrated their prom at Blue Grillhouse in Bethlehem on Friday. Freelance photographer Tim Wynkoop was there to capture a few moments during their prom.

Eli Lilly is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so.Trading at $852 per share, LLY ...

Pharmaceutical giant Eli Lilly and Co. sued Willow Health Services and three other companies in federal court in New Jersey and California, accusing them of selling unapproved compounded ...

April 25 (Reuters) - Eli Lilly (LLY.N), opens new tab has requested Europe's medicines regulator to re-examine its opinion on the company's Alzheimer's drug, the agency said on Friday. Last month ...

A Houston-based compounding pharmacy that was recently roped into Eli Lilly’s fight against knockoff GLP-1s has landed in the FDA’s crosshairs for the second time in less than a year.

The Tempo pen is currently compatible with three of Lilly's insulin products, including Humalog and Lyumjev, both insulin lispro-based, and insulin glargine brand Basaglar. "Despite technological ...

A Greenwich native is aiming to bring the scents of Palm Beach, Florida, to the whole nation. Jayne Chase will sell her Perfectly Palm Beach Candles and Diffusers product during an event at the ...

Eli Lilly's Orforglipron shows promising Phase III results, potentially becoming a best-in-class oral GLP-1 receptor agonist for diabetes and obesity by 2026. Despite macroeconomic headwinds ...